Objective To investigate the appropriate range of gestational weight gain in pregnant women with abnormal glucose metabolism.Methods A retrospective study was conducted on 661 term singleton pregnant women with gestational abnormal glucose metabolism,who delivered in the Department of Obstetrics and Gynecology of Peking University First Hospital from Jan.2005 to Dec.2007,by reviewing the medical records.All sujects were divided into 4 groups according to their body mass index (BMI) before pregnancy:group Ⅰ (n=40):BMI<18.5;group Ⅱ (n=400):BMI18.5-23.9;group Ⅲ (n=162):BMI 24.0-27.9;group Ⅳ (n=59):BMI≥28.0.The weight gain among different groups and that between women who delivered normal birth weight infant and maerosomia were analyzed.The weight gain of pregnant women who delivered babies weighing 3000～3500 g in each group was determined as the appropriate weight gain for that group.Results The same results were achieved that the weight gain in pregnant women who delivered macrosomia was significantly higher than those who delivered normal birth weight newborns in each group,ie,the weight gains for women who had macrosomia and normal birth weight infants were (17.0±5.2) kg and (14.1±4.7) kg in group Ⅱ,(16.8±7.3) kg and (11.9±5.1) kg in group Ⅲ and (18.3±6.7) kg and (11.2±5.4) kg in group Ⅳ,respectively (P<0.05).The appropriate ranges of weight gain for each group were (15.6±3.3) kg,(14.0-18.0) kg for group Ⅰ,(13.9±4.6) kg,(11.0-16.5) kg for group ]],(11.5±5.2)kg,(9.0-15.0) kgforgroup Ⅲ,(10.1±2.9) kg,(7.0-12.7) kg forgroup Ⅳ.Conclusions Appropriate weight gain based on prepregnant BMI,together with glucose monitoring in women with gestational abnormal glucose metabolism,is helpful for fetal weight control.

Objective To examine the age-related morphological changes in hair cell nuclei,and explore the death modes of cochlea hair cells in aged rats.Methods Thirty-two Wistar rats were used in present experiment.The animals were assigned to one of the two groups,rats in aged group(n=20)were 22-23 months of age,and those in young group(n=12)were 2-3 months of age.The auditory brainstem response(ABR)thresholds of both ears elicited with tone bursts at 4,10 and 20 kHz were measured in both young and aged Wistar rats.Upon completion of the auditory test,animals were decapitated and both left and right bullae were exposed.Following fixation,whole specimens comprising the basilar membrane with Corti's organ were separated from the modiolus.Propidium iodide(PI),a popular DNA intercalating fluorescent probe,was used to trace the morphological changes in cochlea hair cell nuclei in the aged rats.Each Corti's organ was thoroughly inspected from the apical to the basal turns of cochlea with fluorescence microscopy.According to the morphological changes in the nuclei,the death modes of cochlea hair cell were determined.Results There were significant differences on ABR thresholds(P=0.001)at all tested frequencies between the young and aged rats.Three types of cochlea hair cell pathology appeared in the aged rats,including karyopyknosis,nuclear swelling and denucleation.A large number of loss or degenerated hair cells were present in the apical and basal end of cochlea in aged rats.Conclusion The present study indicates that apoptosis and necrosis are the death modes of cochlea hair cells in aged Wistar rats.

To explore the mechanism of therapeutic effect of basic fibroblast growth factor (bFGF) in the treatment of blast-induced deafness, and to define its optimal clinical use, bFGF was infused into the guinea pig's cochlea, combined with intramuscular injection of bFGF after being exposed to explosion. The compound action potential (CAP) and auditory brainstem response (ABR) were measured in these animals. 125I labeled basic fibroblast growth factor ( 125I -bFGF) was injected intraperitoneal to the guinea pigs to observe whether it could pass through the blood-labyrinthine barrier. The results showed that bFGF infused to the cochlea might facilitate recovery of hearing loss following acoustic trauma. Basic fibroblast growth factor ( 125I -bFGF) intraperitoneally injected, could not pass through the blood-labyrinthine barrier. However intramuscular bFGF promoted the recovery of hearing, probably indirectly through the neuro-immunity network.

Objective To investigate the influencing factors of neonatal birth body mass in women with abnormal glucose metabolism during pregnancy. Methods A study was conducted on 1157 singleton gravidas, who were diagnosed and treated for abnormal glucose metabolism and delivered in the Department of Obstetrics and Gynecology, First Hospital, Peking University from January 2005 to December 2009, by reviewing the medical records. Based on the pre-pregnant body mass index, the selected cases were divided into 4 groups: low body mass group [ body mass index (BMI) ＜ 18.5 kg/m2, n =53], ideal body mass group ( BMI 18.5 - 23.9 kg/m2, n = 647 ), over body mass group ( BMI 24.0 - 27.9 kg/m2, n = 323 ),and obese group (BMI≥28.0 kg/m2, n = 134). 1157 newborns were divided by birth body mass into 3 groups: normal birth body mass group (body mass 2500 -4000 g, n =987), of which 545 cases of birth body mass 3000 -3500 g for the appropriate newborns, macrosomia group (body mass≥4000 g, n = 112);low birth body mass group (body mass ＜ 2500 g, n = 58 ). The following information was collected,including pre-pregnancy body mass, height, gestational age of diagnosis and body mass gain after diagnosis,maternal serum level of cholesterol, history of adverse pregnancy, and family history of diabetes, gestational age, delivering body mass, neonatal birth body mass. The influence of pre-pregnant BMI, body mass gain during pregnancy, gestational age of diagnosis, body mass gain after diagnosis, maternal serum level of cholesterol, family history of diabetes on the newborns' birth body mass was analyzed. The appropriate ranges of gestational body mass gain were calculated in women with abnormal glucose metabolism. Results ( 1 )The average neonatal birth body mass for each group respectively were (3142 ±333) g for low body mass group, (3339 ±476) g for the ideal body mass group, (3381 ±581) g for over body mass group, and (3368 ± 644) g for obese group. The neonatal birth body mass was increasing with maternal pre-pregnant BMI, and average birth body mass of the newborns in low body mass group was lower than other 3 groups,respectively, the difference was statistically significant ( P ＜ 0.05 ). The difference was not statistically significant ( P ＞ 0.05 ), when it was compared among the obese group, ideal weight group and over body mass group. (2)The body mass gain during pregnancy in women delivered normal birth weight newborn and delivered macrosomia for each group respectively were ( 13.5 ±4.5 ) and ( 17.1±5.4) kg for the ideal body mass group, ( 11.6 ± 4.9 ) and ( 15.3 ± 6.4 ) kg for the over body mass group, ( 10.3 ± 5.0) and ( 14.7 ±7.4) kg for the obese group. The difference was statistically significant in 3 groups (P ＜ 0.05 ). The difference of body mass gain during pregnancy in women delivered normal birth weight newborn and delivered macrosomia for low body mass group could not be compared statistically, because of only 1 case delivered macrosomia. (3)The gestational age of diagnosis in women who delivered normal birth weight newborn and macrosomia for the ideal body mass group respectively were ( 27.8 ± 5.8) and ( 29.8 ± 5.3 ) weeks, the difference was statistically significant ( P ＜0.05 ). The gestational age of diagnosis in gravidas who delivered normal birth weight newborn and macrosomia for the over body mass group respectively were ( 26.7 ± 6.8)and (30.2 ± 4.1 ) weeks, the difference was statistically significant ( P ＜ 0.05 ). The gestational age of diagnosis in women who delivered normal birth weight newborn for obese group was (26.2 ± 7.5 )weeks, less than that of pregnant women who delivered macrosomia [ ( 25.7 ± 9.3 ) weeks ], but the difference was not statistically significant (P ＞ 0.05 ). The difference of the diagnosed gestational age for low body mass group could not be compared statistically, because of only 1 case delivered macrosomia. (4)Tbe serum triglyceride (TG) levels of pregnant women who delivered macrosomia was (3.1 ± 1.5) mmol/L, higher than that of pregnant women who delivered normal birth weight newborn [ (2.7 ± 1.2) mmol/L], and the difference was statistically significant (P ＜ 0.01 ). The serum high density lipoprotein cholesterol (HDL-C) levels of pregnant women who delivered macrosomia was ( 1.4 ± 0.3 ) mmol/L, lower than that of pregnant women who delivered normal birth weight newborn [( 1.7 ±0.9) mmol/L], and the difference was statistically significant (P＜0.01). The serum low-density lipoprotein cholesterol (LDL-C) and cholesterol level of pregnant women who delivered macrosomia respectively was ( 2.8 ± 0.8 ) and ( 5.4 ± 1.1 ) mmol/L, less than those of pregnant women who delivered normal birth weight newborn [ (3.0 ±0.9) mmol/L and (5.6 ±1.1) mmol/L], but the difference was not statistically significant (P ＞0.05). (5)The final regression model of variables into the top three were pre-pregnant BMI, body mass gain during pregnancy and maternal serum level of HDL-C, when analyzing the related factors of affecting neonatal birth body mass with multiple logistic regression analysis such as age, history of adverse pregnancy, family history of diabetes, prepregnancy BMI, body mass gain during pregnancy and after diagnosis of abnormal glucose metabolism,maternal serum level of cholesterol, abnormal glucose metabolism categories, gestational age and other factors ( P ＜ 0.01 ). Conclusion Pre-pregnant BMI, body mass gain during pregnancy and maternal serum level of HDL-C may affect the neonatal birth body mass whose mothers were complicated with abnormal glucose metabolism during pregnancy.

Primary immune thrombocytopenia ( ITP) is an organ-specific autoimmune hemorrhagic disease. The etiology of ITP is still unclear, but loss of immune tolerance to platelet surface antigens is con-sidered as a fundamental cause of ITP. Therapeutic strategies that prevent the activation and proliferation of autoreactive cells have been suggested, which includes clearance of autoreactive cells ( apoptosis) , receptor editing, induction of anergy and extrinsic cellular suppression. Failure at any of these steps may lead to the production of autoantibodies against platelet and megakaryocyte glycoproteins. An improved understanding of the mechanisms for autoantibody production will provide theoretical basis for optimal diagnosis and treatment of ITP.

Objective To investigate clinical effect of patients with PICU multiple organ dysfunction by continuous blood filtration combined with naloxone.Methods 42 patients with multiple organ function failure were selected and randomly divided into 2 groups.The control group were treated by PICU conventional therapy, the experiment group were treated by continuous blood filtration combined with Naloxone.Vital signs, creatinine, creatine kinase and aspartate aminotransferase levels, length of stay and blood filtration were compared after 1 day and 3 days treatment.ResuIts Compared with control group,heart rate, oxidation index,creatinine and aspartate aminotransferase levels of the experiment group were lower(P<0.05).After 1 day and 3 days, compared with cnontrol group, length of stay and blood filtration of the experiment were lower(P<0.05).ConcIusion Continuous blood filtration combined with naloxone in treatment of multiple organ dysfunction syndrome PICU is effective and reliable.It can significantly improve renal function, shorten the length of hospital stay, and remove inflammatory mediators in plasma of patients.

Objective: To explore effects of large dose gamma globulin on cardiac function and immune regulation in patients with dilated cardiomyopathy (DCM) and heart failure (HF).Methods: According to random number table, a total of 90 DCM + HF patients were divided into routine treatment group (n=45) and gamma globulin group (n=45, received gamma globulin based on routine treatment, 400 mg kg-1 d-1 intravenous drip for 5d).After three months, therapeutic effect, cardiac function, levels of cardiac troponin T (cTnT), cTnI, N terminal pro brain natriuretic peptide (NT-proBNP) and anti-cardiac myosin heavy chain auto-antibodies (AMHCA) IgG titer before and after treatment, incidence of adverse reactions were observed and compared between two groups.Results: After three-month treatment, total effective rate of gamma globulin group was significantly higher than that of routine treatment group (80.00% vs.57.50%, P=0.02);compared with routine treatment group after treatment, there were significant reductions in levels of cTnT [(0.54±0.18) μg/L vs.(0.31±0.12) μg/L], cTnI [(1.35±0.18) μg/L vs.(0.72±0.13) μg/L], NT-proBNP [(758.34±64.28) pg/ml vs.(708.34±60.22) pg/ml], and significant rise in left ventricular ejection fraction [LVEF, (39.35±6.23)% vs.(47.32±6.10)%] in gamma globulin group, P<0.05 all;compared with before treatment and routine treatment group after treatment, there was significant reduction in AMHCA IgG titer [(0.099±0.047), (0.092±0.045) vs.(0.069±0.032), P<0.05 both] in gamma globulin group;incidence rate of adverse reaction in gamma globulin group was significantly higher than that of routine treatment group (22.22% vs.6.67%, P=0.04), but the symptoms were mild, and they recovered after symptomatic treatment.Conclusion: Large dose gamma globulin can significantly improve cardiac function and possesses good immune regulation effect in patients with dilated cardiomyopathy and heart failure.

Objective To establish a HPLC method to determine the related substances of vitamin B6 for injection.Methods HPLC method was adopted with DiamonsilTM C18,5μm 250mm×4.6mm;the mobile phrase was length was 291nm.Results The calibration curve was linear in the concentration range of 600～1400μg/ml(r=0.9998).Conclusion The method is simple,rapid,accurate and reliable.As the supplement method of active pharmacopoeia,it can effectively control the quality of the product.

BACKGROUND: The sensorineural deafness occurs as a result of loss of inner ear hair cells in the cochlea or of their primary afferent the spiral ganglion neurons. Stem cells to restore hearing following inner ear cell death has become a focus in recent years.OBJECTIVE: To summarize research progress in stem cells differentiating into inner ear cells in vitro and in vivo and to review the achievement in stem cells replacing inner ear cells in treating sensorineural deafness.METHODS: With "inner ear, stem cells" as key words, a computer-based online search of Pubmed and CNKI was performed for articles published from January 2000 to August 2009. RESULTS AND CONCLUSION: A total of 170 articles were collected, and experimental studies and review articles on stem cells in sensorineural deafness were included, while repetitive articles were excluded. Finally, 32 articles were summarized and analyzed. Different types of stem cells have the capacity to differentiate into inner ear cells. They can differentiate into neural cell types. Stem cells can live and migrate, differentiating into cell types of the sites of injury. It provides a therapy strategy to restore hearing following sensorineural deafness by he capacity of stem cells differentiating into inner ear cells. However, it remains further investigation how to function following cell differentiation and how to form the appropriate neural pathways by stem cell transplantation in sensorineural deafness.

Objective To develop a system for hand function evaluation and training based on virtual reality. Methods 5DT Data Glove 5 Ultra, Visual Studio 2010 were integrated as the development environment and DirectX 9.0 as components, and the system was developed based on the MFC programming framework. Results and Conclusion The system can assess the fingers function, recognise gestures and can be used as a 3D environment for virtual training, which may guide the patients to take the training actively.